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Spinal cord injury (SCI) leads to cardiac atrophy often accompanied by functional
deficits. The renin–angiotensin system (RAS) with angiotensin II (AngII) signalling via
its receptor AT1a might contribute to cardiac atrophy post-SCI. We performed spinal
cord transection at thoracic level T4 (T4-Tx) or sham-operation in female wild-type
mice (WT, n = 27) and mice deficient in AT1a (Agtr1a−/−, n = 27). Echocardiography
(0, 7, 21 and 28 days post-SCI) and histology and gene expression analyses at 1 and
2 months post-SCI were performed. We found cardiac atrophy post-SCI: reduced
heartweight, reduced estimated left ventricularmass inAgtr1a−/−, and reduced cardio-
myocyte diameter in WT mice. Although, the latter as well as stroke volume (SV) and
cardiac output (CO)were reduced inAgtr1a−/−mice already at baseline, cardiomyocyte
diameter was even smaller in injured Agtr1a−/− mice compared to injuredWTmice. SV
and COwere reduced inWTmice post-SCI. Ejection fraction and fractional shortening
were preserved post-SCI in both genotypes. Therewere nohistological signs of fibrosis
and pathology in the cardiac sections of either genotype post-SCI. Gene expression of
Agtr1a showed a trend for up-regulation at 2months post-SCI; angiotensinogenwas up-
regulated at 2 month post-SCI in both genotypes. AngII receptor type 2 (Agtr2) was
up- and down-regulated at 1 and 2months post-SCI inWTmice, respectively, andAng-
(1-7) receptor (Mas) at 1 and 2months post-SCI. Atrogin-1/MAFbx andMuRF1, atrophy
markers, were not significantly up-regulated post-SCI.Our data show that lack of AT1a
does not protect from cardiac atrophy post-SCI.
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1 INTRODUCTION
Cardiovascular dysfunction is a major problem for people with spinal
cord injury (SCI), affecting both mortality and morbidity (Weaver,
Fleming, Mathias, & Krassioukov, 2012). Development of cardio-
vascular risk factors (Cragg, Noonan, Krassioukov, & Borisoff, 2013)
and potentially also cardiac pathology contribute to the elevated risk
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of heart disease in this patient group. Acute cardiac damage upon
SCI in autopsy as well as in experimental animals is mediated by
calcium excitotoxicity and massive noradrenaline release (Sharov &
Galakhin, 1984). In chronic experimental SCI cardiac atrophy with
systolic dysfunction and reduced contractility appear (Poormasjedi-
Meibod et al., 2019; West et al., 2014), whereas in patients cardiac
atrophy and stroke volume reduction are not accompanied by ejection
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fraction reduction, and thus it is considered that no dysfunction exists
(Driussi et al., 2014; Williams, Gee, Voss, & West, 2019). Cardiac
atrophy results from loss of supraspinal sympathetic control over
the heart and vasculature and cardiac unloading post-SCI, which is
caused by reduced venous return and activity (Lujan & Dicarlo, 2014;
Squair et al., 2018). Cardiac unloading in turn activates the ubiquitin-
proteasome system (UPS) and the autophagy-lysosomal machinery
(Poormasjedi-Meibod et al., 2019; Zaglia et al., 2013). Further research
is required in order to identify and verify players in this physiological or
pathological process.
The renin–angiotensin system (RAS) and activation of its classical
axis with elevated angiotensin II (AngII) and expression of one of its G-
protein-coupled receptors, AngII receptor type 1a (AT1a), could be a
double-edged sword in the heart following SCI (Groothuis et al., 2010;
Mathias, Christensen, Frankel, & Peart, 1980; Poormasjedi-Meibod
et al., 2019). For example, AngII/AT1a signalling aggravates skeletal
muscle atrophy by activation of UPS and autophagy (Burks et al., 2011;
Cabello-Verrugio, Cordova, & Salas, 2012). Furthermore, blocking of
this signalling has prevented left ventricular remodelling in a cachexic
cardiac model (Stevens et al., 2015; Yoshida et al., 2013). At the
same time, AngII/AT1a is mediating myocyte hypertrophy, fibroblast
proliferation, collagen synthesis, smooth muscle cell growth, end-
othelial adhesion molecule expression and catecholamine synthesis
(Regitz-Zagrosek, Fielitz, & Fleck, 1998). The role of AngII/AT1a
following SCI remains unclear.
We hypothesized that mice lacking AT1awould present less cardiac
atrophy and dysfunction post-SCI, e.g. by less activated UPS. If so,
this could provide a therapeutic strategy to protect the heart post-
SCI. To test this hypothesis, we performed spinal cord transection
at thoracic level T4 (T4-Tx), which is supposed to lead to reduction
of approximately 75% of sympathetic innervation to the heart from
the stellate ganglion (Strack, Sawyer, Marubio, & Loewy, 1988), or
sham-operation in WT and Agtr1a−/− mice. We investigated heart
structure/function by echocardiography combined by histological and
gene expression analysis at 1 and 2months post-SCI.
2 MATERIALS AND METHODS
2.1 Ethical approval
Experiments were conducted according to the National Institutes of
Health Guide for the Care and Use of Laboratory Animals, and the ethical
principles under which the journal operates: our work complies with
the journal’s animal ethics checklist. The protocols were approved
by the local Animal Care and Use Committee from Berlin LAGeSo
(G0132/14).
2.2 Mice and experimental protocol
All mice were housed in groups of four to six animals in cages with
nesting material, mouse lodges and open access to water and food, at
New Findings
∙ What is the central question of this study?
What is the role of the renin–angiotensin system
with angiotensin II acting via its receptor AT1a in
spinal cord injury-induced cardiac atrophy?
∙ What is themain finding and its importance?
Knockout of AT1a did not protect mice that had
undergone thoracic level 4 transection from cardiac
atrophy. There were no histopathological signs but
there was reduced load-dependent left ventricular
function (lower stroke volume and cardiac output)
with preserved ejection fraction.
23◦C with a 12 h/12 h circadian cycle. Experiments were performed
using female wild-type C57Bl/6 J (WT, Agtr1a+/+) vs. AT1a receptor-
deficientmice (B6.129P2-Agtr1atm1Unc/J fromThe Jackson Laboratory,
Bar Harbor, MA, USA) (Agtr1a−/−), weighing 20–25 g, and at about
3months of age.
The first group of mice (Agtr1a+/+ sham n = 6, SCI n = 7; Agtr1a−/−
sham n = 5, SCI n = 8) were killed with an overdose of intraperitoneal
ketamine (140 mg kg−1)–xylazine (14 mg kg−1) anaesthesia 1 month
post-SCI. The second group (Agtr1a+/+ sham n= 7, SCI n= 7;Agtr1a−/−
sham n = 7, SCI n = 7) was killed as described above at 2 months post-
SCI. Cardiac tissue from both 1- and 2-month groups was analysed
by histology and qPCR. All data analysis (echocardiography, histology,
qPCR, cardiomyocyte diameter) was conductedwith the experimenter
blinded to the different genotype and injury/sham group, except in the
echocardiography injury/sham group, where the experimenter could
not be blinded.
2.3 SCI
SCI was performed under intraperitoneal ketamine (100 mg kg−1)–
xylazine (10mg kg−1) anaesthesia in combination with isoflurane (1.5–
1.8%) inhalation as described previously (Jarve et al., 2018). Briefly, a
dorsalmidline incisionwasmade in the superficialmuscle overlying the
C7–T3 vertebrae. The dura was opened at the T2–T3 intervertebral
gap and the spinal cordwas completely transected usingmicroscissors.
Complete transectionwas confirmedbypulling aneedle twicebetween
the rostral and caudal spinal cord stumps. Gelfoam was placed above
spinal cord to achieve haemostasis. The muscle and skin were closed
with absorbable sutures (Vicryl, 4–0, Ethicon GmbH, Norderstedt,
Germany). Animals received warmed saline (1 ml, S.C.), recovered and
were kept in heated cages (30◦C) for the rest of the experiments. For
analgesia mice were treated with carprofen (4 mg kg−1, S.C.) directly
after operation and the next day with a 12 h interval, if necessary
longer. The bladder was manually emptied three times daily for the
whole duration of the experiment.
1318 JÄRVE ET AL.
2.4 Echocardiographic studies
Two-dimensional echocardiographic imaging was performed under
isoflurane anaesthesia 1 day before and 7, 21 and 28 days post-
injury/sham-surgery (dpi) using the Vevo 700 high-resolution in vivo
ultrasound technology (VisualSonics, Toronto, Canada) equipped with
an MS-400 scan head with transmission frequency of 30 MHz.
Anaesthesia was induced with isoflurane 3% and maintained with
(1.6 vol% isoflurane–air). Body temperature was maintained through
a heating pad at 37◦C. Images were acquired for further off-line
analysis by a single operator of theMaxDelbrückCenter forMolecular
Medicine Animal Phenotyping Platform blinded for genotype. Left
ventricular (LV) end-diastolic andend-systolic diameter (LVIDd, LVIDs),
ejection fraction (EF), stroke volume (SV) and heart rate (HR)
were determined by tracing of endocardial and epicardial borders
and majors in end-diastole and in end-systole in the parasternal
long axis view. LV end-diastolic and end-systolic posterior wall
thickness (PWTd, PWTs) and anteriorwall (interventricular septalwall)
thickness (IVSd, IVSs) were determined by tracing at end-diastole
and at end-systole in the parasternal short axis view. Fractional
shortening (FS, %), cardiac output (CO, ml min−1) and LV mass were
calculated:
FS= 100× [(LVIDd – LVIDs)/LVIDd]
CO= SV×HR/1000
LVmass= 1.053× [(LVIDd+ LVPWd+ IVSd)3 – LVIDd3].
2.5 Quantitative RT-PCR
Hearts were halved so that the apex-facing part was processed
further for RNA isolation and real-time qPCR analysis and the
upper part was used for histology. For RNA isolation with Trizol
and FastPrep beads, the manufacturer’s instructions were followed.
Reverse transcription was performed with 2 μg total RNA using
Moloney murine leukaemia virus with digestion by incubation with
1 μl DNase I (Roche Applied Science, Mannheim, Germany). Real-
time PCR was performed with a QuantStudio 5 Real-Time PCR
System (Thermo Fisher Scientific, Waltham, MA, USA) according
to the manufacturer’s recommendations by using SYBR Green; the
amplicon detected by SYBR Green was verified by a melting point
analysis. Each cDNAsamplewas tested in triplicate, and the expression
level of each gene was normalized to the hypoxanthine-guanine
phosphoribosyltransferase (Hprt) level. The primers used are listed in
Table 1. The fold changewas determined using the 2−ΔΔCt method.
2.6 Histology
Hearts were dissected without the great vessels and their weight
determined. Upper halves of the hearts were incubated in KCl for
10 min, fixed for 48 h in 4% paraformaldehyde in buffered saline (pH
7.4) at 4◦C, washed, dehydrated, embedded in paraffin, sectioned at
5 μm with a rotary microtome (Microm; Thermo Fisher Scientific),
TABLE 1 Quantitative real-time PCR targets and their primer
sequences


















Murf1, muscle ring finger 1; MAFbx, muscle atrophy F-box; Agt,
angiotensinogen; Agtr1a, Ang II type 1 receptor type a; Agtr2, Ang II
type 2 receptor;Mas, MAS1 proto-oncogene, G protein-coupled receptor.
placed on SuperFrost Plus slides (Thermo Fisher Scientific) and stored
at room temperature until use. For picro-Sirius red staining, paraffin
sections were deparaffinized, rehydrated and stained by incubation
with picro-Sirius red solution (0.1%Sirius redF3B in saturated aqueous
solution of picric acid) for 1 h at room temperature. After two washes
with acidified water (0.5% glacial acetic acid in tap water), sections
were dehydrated in three changes of 100% ethanol, cleared using
xylene and coverslipped using Eukitt (ORSAtec GmbH, Bobingen,
Germany). Four non-consecutive sections with haematoxylin–eosin
(HE) and Sirius red staining permousewere analysed using an inverted
microscope (BZ-9000; Keyence, Osaka, Japan).
For quantification of cardiomyocyte diameter, at the mid-
ventricular level wheat germ agglutinin (WGA) stainingwas performed
by incubating deparaffinized and rehydrated heart sections with
WGA+Al488 conjugate (1:300) (Thermo Fisher Scientific) for 20 h
at 4◦C, washed three times with phosphate-buffered saline for
10 min each and coverslipped using Vectashield (Vecta Laboratories,
Burlingame, CA, USA) mounting medium containing 4′,6-diamidino-2-
phenylindole. To evaluate cardiomyocyte diameter, images were taken
using an invertedmicroscope (BZ-9000) and 610–980 cardiomyocytes
per groupwere analysed using BZ-II Analyzer software (Keyence).
2.7 Power analysis
There has been no previous echocardiography study in mice with SCI.
A power analysis based on the study of West et al. (2014) in rats with
SCI showed that a sample size of two mice per group has a 80% power
to detect a 12% change of LVIDd, 26% change of SV and 28% change in
JÄRVE ET AL. 1319
1320 JÄRVE ET AL.
CO, assuming a5%significance level and a two-sided test.Our previous
echocardiography study of mice 1 month post-myocardial infarction
showed that we would need seven to eight mice in order to see a 12%
change of LVIDd and25%change in FS assuming a 5% significance level
and a two-sided test. Therefore, the group size in echocardiography
experiment was five to eight mice.
2.8 Statistics
Data were analysed statistically using Prism 5 software (GraphPad
Software, San Diego, CA, USA) and SPSS Statistics (IMB Corp.,
Armonk, NY, USA). Echocardiography data were analysed using two-
way repeated measures (RM) ANOVA with a Bonferroni post hoc test.
Two-way ANOVAwas conducted on the influence of two independent
factors (surgery and genotype) on heart weight and cardiomyocyte
diameter. Surgery type included two levels (sham and SCI) and
genotype consisted of two levels (WT, KO). qPCR data fold changes
were analysed with one-way ANOVA followed by a post hoc test.
Significance for all tests was assumed when P < 0.05. Results are pre-
sented asmeans± SD.
3 RESULTS
3.1 Echocardiography: reduced SV and CO,
but preserved FS and EF post-SCI
Structural changes following SCI observed in echocardiography
included reduction of the estimated LV mass at 21 and 28 dpi (2-way
RM ANOVA Bonferroni post hoc test, P < 0.001 and P < 0.01) as
well as of IVSd at 21 dpi in Agtr1a−/− mice vs. pre-injury values in
these mice (2-way RM ANOVA Bonferroni post hoc test, P < 0.001)
(Figure 1a,b). LVIDd was smaller in injured vs. sham WT mice at 21
and 28 dpi (2-way RM ANOVA Bonferroni post hoc test, P < 0.01 and
P < 0.05) as well as in injured vs. sham Agtr1a−/− mice at 28 dpi (2-way
RM ANOVA Bonferroni post hoc test, P < 0.05) (Figure 1c). LVIDs was
smaller in WT sham vs. injured mice at 21 dpi (2-way RM ANOVA
Bonferroni post hoc test, P < 0.05) (Figure 1d). Functional changes
upon SCI comprised a reduced SV at 28 dpi inWT sham vs. WT injured
mice and within WT injured mice vs. pre-injury values (2-way RM
ANOVA Bonferroni post hoc test, P < 0.05 and P < 0.01) (Figure 1e).
SV was lower in Agtr1a−/− sham mice vs. WT sham mice (pre-surgery,
7, 21 days post-surgery) and in baseline measurement of T4-Tx WT
vs. T4-Tx Agtr1a−/− mice (2-way RM ANOVA Bonferroni post hoc test,
all P < 0.05). CO was lower following SCI in WT mice at 28 dpi vs.
pre-injury (2-way RM ANOVA Bonferroni post hoc test, P < 0.01) and
in Agtr1a−/− sham vs. WT sham (pre-surgery, 7, 21 days post-surgery
2-way RM ANOVA Bonferroni post hoc test, all P < 0.05) (Figure 1f).
There were no significant differences in EF and FS post-SCI, nor in HR,
IVSs, LVIDs, PWTd and PWTs (2-way RM ANOVA Bonferroni post hoc
test, all P > 0.05) (Figure 1g–l). Two-way RM ANOVA did not reveal
any significant interaction between the treatment group and the time
factor for any of the analysed echocardiography parameters. For LV
mass the interaction effect has borderline significance (P= 0.0551). In
order to investigate whether the effect of SCI on LV mass is different
in Agtr1a−/− mice compared to WT, we plotted the mean difference
in the change in LV mass with SCI vs. sham in WT vs. knockout mice,
together with 95% confidence intervals (CI), at each time point post-
surgery (Figure 1m) and the adjusted mean differences (Figure 1n).
LV mass decreased at 7 dpi (−15.2 (95% CI: 0.3, −30.7) g), at 21 dpi
(−26.6 (95% CI: −16.3, −36.9) g) and at 28 dpi (−21.4 (95% CI: −13.7,
−29.1) g) in KO, and at 7 dpi (−4.1 (95% CI: 21.8, −30.0) g), at 21
dpi (−12.6 (95% CI: 9.3, −34.5) g) and at 28 dpi (−3.1 (95% CI: 22.4,
−28.6) g) inWT.
3.2 Reduced cardiac weight and cardiomyocyte
diameter following SCI, but proportional to body
weight reduction
Mice with SCI had smaller heart weight (HW) and HW/tibia length
ratios (HW/TBL) compared to sham mice independent of their
genotype at 1 and 2 months post-SCI (2-way ANOVA, all P < 0.006)
(Figure 2a,b). Therewas no statistically significant interaction between
the effects of surgery and genotype level in HW or HW/TBL at 1 and
2 months post-SCI (all F < 0.949, P > 0.340. Main effect of genotype
was also not significant (all F< 1.807, P> 0.196).
The ratio of HW/body weight (BW) did not differ between sham
and injured mice of both genotypes, but tended to be smaller in the
shamAgtr1a−/−mice compared toWT shammice (2-wayANOVA, both
P> 0.090) (Figure 2c).
Histological analysis of the diameter of cardiomyocytes at the
mid-ventricular level was performed. Two-way ANOVA revealed a
significant interaction between surgery type (T4-Tx vs. sham) and
genotype (WT vs. KO) (P < 0.0001). The main effects of surgery
and genotype both reached the higher significance (P < 0.0001)
(Figure 2d).
F IGURE 1 Echocardiography before and after SCI in theWT and Agtr1a−/− mice. (a) Left ventricular mass (LV), (b) interventricular septum
thickness at diastole (IVSDd), (c) LV internal diameter at diastole (LVIDd), (d) LV internal diameter at systole (LVIDs), (e) stroke volume (SV), (f)
cardiac output (CO). (g–l) Ejection fraction (g) and fractional shortening (FS) (h), heart rate (HR) (i) and interventricular septum thickness at systole
(IVSs) (j), and posterior wall thickness at diastole (PWTd) (k) and systole (PWTs) (l) were not regulated post-SCI. Two-way RMANOVAwith
Bonferroni post hoc test: ##P< 0.01, ###P< 0.001, KO pre- vs. post-SCI; *P< 0.05, **P< 0.01,WT sham vs. WT SCI; †P< 0.05, ††P< 0.01,WT pre
vs. post-SCI; ‡P< 0.05WT SCI vs. KO SCI; §P< 0.05 KO sham vs. KO SCI; ¶P< 0.05, ¶¶P< 0.01,WT sham vs. KO sham. Data are displayed as
means± SD. (m)Mean change in LVmass (LVmass at given time point is subtracted from pre-surgery value) and 95% confidence interval at
indicated time points in Agtr1a−/− sham and SCI mice and Agtr1a+/+ sham and SCI mice, (n) the same analyses adjusted for chance imbalance at
baseline by including baseline LVmass as covariate
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F IGURE 2 Cardiac atrophy and cardiomyocyte diameter post-SCI. (a–c) Heart weight (a) and its ratio with tibia length (b), but not its ratio with
bodyweight (c) were reduced in injured vs. shammice at 1 and 2months post-SCI. (d) Cardiomyocyte diameter mean values with 0.95% confidence
intervals 1month post-surgery. Significant results of 2-way ANOVA are presented above the figures.WT sham 1month n= 6 and 2months n= 7;
WT T4-Tx 1month n= 7 and 2months n= 7, Agtr1a−/− sham 1month n= 5 and 2months n= 7; Agtr1a−/− T4-Tx 1month n= 8 and 2months n= 7
3.3 No signs of inflammation or fibrosis 1 month
post-SCI
The myocardium of SCI mice had normal histology, with no signs of
infiltration of monocytes and macrophages, cardiomyocyte necrosis
in HE stained cardiac slices. Picro-Sirius red staining revealed no
significant blood vessel-associated or interstitial fibrosis (Figure 3).
3.4 Atrogene and RAS expression post-SCI
Next we investigated the regulation of the genes involved in atrophy
and members of the RAS. Gene expression of muscle atrophy F-
box (MAFbx) showed a trend for down-regulation and up-regulation
at 1 and 2 month post-SCI, respectively, in WT mice compared to
sham (1-way ANOVA, P > 0.05) and RING-finger protein-1 (Murf1)
had no significant regulation (1-way ANOVA, P > 0.05) (Figure 4a,b).
Angiotensinogen was up-regulated at 2 months post-SCI in Agtr1a−/−
and WT mice compared to sham (1-way ANOVA with Bonferroni post
hoc test, all P < 0.05) (Figure 4c). AngII receptor AT2 (Agtr2) was
up-regulated at 1 month post-SCI in WT mice (1-way ANOVA with
Bonferroni post hoc test, P < 0.05) (Figure 4d). The expression of Mas
was down-regulated at 1 and 2months post-SCI inWTand at 2months
post-SCI in knockout mice (1-way ANOVA with Bonferroni post hoc
test, all P< 0.05) (Figure 4e). Agtr1awas not significantly regulated (1-
way ANOVAwith Bonferroni post hoc test, both P> 0.05) (Figure 4f).
4 DISCUSSION
Major findings of this study include: (i) cardiac atrophy post-SCI with
reduced HW at 1 and 2 months post-SCI in WT and Agtr1a−/− mice
compared to sham mice; reduced cardiomyocyte diameter at 1 month
post-SCI in WT mice; (ii) reduced SV and CO in WT mice at 1 month
post-SCI; (iii) preserved EF and FS at 1 month post-SCI in WT and
Agtr1a−/−mice; (iv) no cardiac pathology and fibrosis at 1 and 2months
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F IGURE 3 Cardiac histology post-SCI was
unchanged compared to shammice.
Representative images of hematoxylin staining
(a–f) and Sirius red staining (g–l). Scale bar:
500 μm
post-SCI; and (v) smaller cardiomyocyte diameter, SV and CO in non-
injured Agtr1a−/− mice compared toWTmice.
Cardiac atrophy post-SCI is caused by loss of sympathetic
innervation (trophic support) to the heart as well as by haemodynamic
unloading, which is a result of reduced blood volume and physical
inactivity (Lujan &Dicarlo, 2014; Squair et al., 2018;West et al., 2014).
In our T4-Tx model, approximately 75% of sympathetic innervation
to the heart from the stellate ganglion must be lost (Strack et al.,
1988) resulting in approximately 18% lighter hearts in injured mice. In
comparison, total chemical denervation leads to about 15% reduction
in HW and this could be prevented by β2-adrenoceptor stimulation,
confirming the trophic effect of sympathetic input (Zaglia et al., 2013).
Bed rest for 6 weeks, on the other hand, resulted in 8% reduced LV
mass (Perhonen et al., 2001). Cardiac atrophy post-SCI likely reflects
physiological adaption to the changed situation, rather than being
pathological. Lack of dramatic histological changes or fibrosis and
preserved EF and FS also support the idea of physiological remodelling.
Activation of the UPS and autophagy mediates cardiac atrophy
following denervation. In the SCI, UPS activation occurs at the same
time as atrophy in the Zucker rat (Poormasjedi-Meibod et al., 2019).
In our study, UPS was not changed at 2 months post-SCI, and it might
needmore time to be up-regulated or it may also be that these systems
have been up-regulated early after SCI and later down-regulatedwhen
physiological remodellingwas completed. The species difference could
be also responsible for this discrepancy betweenmice and rats.
Could cardiac atrophy bemediated byAngII/AT1a similar to skeletal
muscle atrophy? Prerequisites for that are fulfilled. AngII levels and
expression of Agtr1a at 3 months post-SCI have been reported to be
elevated (Groothuis et al., 2010; Poormasjedi-Meibod et al., 2019). In
agreement with this, we observed a trend for up-regulation of Agtr1a
at 2 months post-SCI. Our hypothesis that AT1a contributes to the
cardiac atrophy post-SCI was not confirmed, because Agtr1a−/− mice
hearts were not less atrophied post-SCI. Indeed, the opposite might
be true. LV mass and IVSd were significantly reduced following SCI,
and cardiomyocyte diameter at 1 month post-SCI was smaller in the
knockout mice indicating that AT1a contributes to trophic support to
the heart after SCI. Without SCI, HW/BW of Agtr1a−/− mice tended
to be smaller similarly to a previous report (Gembardt et al., 2008).
Cardiomyocyte diameter was also smaller compared to sham WT
mice. Thus, physiological signs of atrophy in Agtr1a−/− mice before
and progression of atrophy following SCI indicates the importance
of AT1a for cardiomyocyte growth stimulation in the heart (also not
compensated by Agtr1b, the expression level of which is very low in the
heart). Note that, except for smaller size, hearts of Agtr1a−/− mice are
structurally normal and there is no dysfunction in echocardiography as
we and others found (Gembardt et al., 2008; Sato et al., 2013).
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F IGURE 4 Gene expression of atrogenes and RASmembers in the heart at 1month and 2months post-SCI inWT and Agtr1a−/− mice. (a) No
regulation inmuscle atrophy F-box (MAFbx) and (b) muscle ring finger 1 (Murf1) expression. (c) Up-regulation of angiotensinogen at 2months
post-SCI. (d) Up-regulation of Agtr2 inWTmice at 1month post-SCI. (e)Maswas down-regulated at 1 and 2months post-SCI inWT and at
2months in Agtr1a−/− mice. (f) Agtr1awas not significantly regulated. *P< 0.05, **P< 0.01, ***P< 0.001, 1-way ANOVAwith Bonferroni post hoc
test.WT sham n= 10;WT T4-Tx 1month n= 7 and 2months n= 7; Agtr1a−/− sham n= 9; Agtr1a−/− T4-Tx 1month n= 8 and 2months n= 7
Would blocking of the AngII/AT1 pathway be beneficial to the heart
post-SCI similar to the cardiac cachexiamodel? Blocking of AngII/AT1a
pathway by losartan in a model of murine tumour-induced cachexia
preventedboth theLVwall thinningand thedecrease inEFand lowered
cardiac geneexpression levels ofMAFbxandautophagygenes (Stevens
et al., 2015). On the other hand improved function and remodelling
noted in the tumour-bearing mice treated with losartan could also be
caused by a significant hypotensive effect of losartan, e.g. by decrease
in afterload (Scherrer-Crosbie, 2015). Because of prevalent hypo-
tension post-SCI (Jarve et al., 2018), blocking of the AngII/AT1a axis
would be detrimental following SCI. No beneficial effect to the heart
could be expected, which is the opposite of the situation of hyper-
tension and overload where blocking of AngII/AT1 activation protects
from hypertrophy and fibrosis of the heart (Kurdi & Booz, 2011).
We observed no fibrosis in the heart post-SCI in contrast to an
earlier report on a trend for higher signal for collagen I in cardiac
sections post-SCI (West et al., 2014). In the human heart, AngII does
not directly increase collagen or fibronectin mRNA (Kupfahl et al.,
2000). AT1 is not (or its absence is not) connected to the basal
production of connective tissue in the heart (van Esch et al., 2010).
Thus, in the absence of obvious inflammation in the heart as after
SCI in contrast to myocardial infarction, activation of the RAS is not
contributing to fibrosis.
4.1 Limitations
With small group sizes this study does not have sufficient power
and precision to statistically undermine all detected effects, and
therefore some findings must be confirmed in the future with a
larger number of animals. EF was used here as the only measure of
cardiac function. This might be critical in the setting of SCI, in which
extreme changes in volume occur (Poormasjedi-Meibod et al., 2019;
Williams et al., 2019). In further studies also parameters related to
diastolic function (E, A, E/A) should be measured. As mice with SCI
did not recover bladder function during the experiments, we cannot
exclude the possibility that manual emptying of bladders might have
affected our results, e.g. by inducing autonomic dysreflexia. However,
we consider the possible effect negligible, taking into account that an
hour-long similar procedure for amonthwould cause further reduction
of basal contractility but not any significant structural alterations
in the heart of exposed animals above that which is observed with
SCI alone (West et al., 2016). Because we used only female mice,
to draw a conclusion for the entire population further experiments
including male mice are warranted. Since a global knockout was used,
the possibility exists that physiological responses to the knockout
in tissues other than the heart might in some unforeseen way
compensate.
1324 JÄRVE ET AL.
5 CONCLUSION
The present study showed that absence of AT1a does not prevent
cardiac atrophy post-SCI. Instead, AngII/AT1a seems to exert trophic
support to the heart before and after SCI.
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